
FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic ...
The FDA issued a complete response letter (CRL) to Aldeyra Therapeutics, the manufacturer of reproxalap, an investigational new drug candidate for the treatment of dry eye disease and allergic conjunctivitis. In the letter, the FDA noted that the new drug …